Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7494.074 | 0.9637 | 0.8937 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7494.074 | 0.9637 | 0.8937 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7494.074 | 0.9733 | 0.9216 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7494.074 | 0.9733 | 0.9216 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7494.074 | 0.7432 | 0.2900 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7494.074 | 0.7432 | 0.2900 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7494.074 | 0.0512 | -0.9753 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7494.074 | 0.0512 | -0.9753 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7494.074 | 0.0139 | -0.9964 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7494.074 | 0.0139 | -0.9964 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7494.074 | 0.0059 | -0.9990 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7494.074 | 0.0059 | -0.9990 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7494.074 | 0.0120 | -0.9971 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7494.074 | 0.0120 | -0.9971 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7494.074 | 0.0077 | -0.9985 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7494.074 | 0.0077 | -0.9985 | 0.6767 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14837.203 | 0.9868 | 0.9828 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 14837.203 | 0.9868 | 0.9828 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14837.203 | 0.9632 | 0.9517 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 14837.203 | 0.9632 | 0.9517 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14837.203 | 0.9466 | 0.9297 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 14837.203 | 0.9466 | 0.9297 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14837.203 | 0.1317 | -0.4669 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 14837.203 | 0.1317 | -0.4669 | 1.5334 | |
| MDA-MB-134-VI | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 14837.203 | 0.0065 | -0.9254 | 1.5334 |